Literature DB >> 16280597

Increased vulnerability to L-DOPA toxicity in dopaminergic neurons From VMAT2 heterozygote knockout mice.

Shingo Kariya1, Nobuyuki Takahashi, Makito Hirano, Satoshi Ueno.   

Abstract

Parkinson's disease (PD) is characterized by a preferential loss of dopaminergic neurons in the substantia nigra pars compacta. The etiology of PD remains unclear; however, generation of reactive oxygen species during oxidation of free dopamine (DA) in the cytoplasm might be one of the causes of selective dopaminergic neuron loss in PD. Vesicular monoamine transporter type 2 (VMAT2) proteins in nerve terminals take up and partition DA from neuronal cytoplasm into synaptic vesicles. Alterations of VMAT2 function might therefore cause cytoplasmic accumulation of free DA, which is toxic for dopaminergic neurons. We showed that dopaminergic neurons from VMAT2 heterozygous knockout mice were more vulnerable to the toxic effect of L-3, 4-dihydroxyphenylalanine (L-DOPA, a DA precursor) than those from wild-type mice. Our results suggest that reduction of VMAT2 activity might attenuate the efficacy of L-DOPA therapy for patients with PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16280597     DOI: 10.1385/JMN:27:3:277

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  11 in total

1.  VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.

Authors:  N Takahashi; L L Miner; I Sora; H Ujike; R S Revay; V Kostic; V Jackson-Lewis; S Przedborski; G R Uhl
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

Review 2.  Parkinson's disease.

Authors:  C D Marsden
Journal:  Lancet       Date:  1990-04-21       Impact factor: 79.321

3.  Dopamine turnover and glutathione oxidation: implications for Parkinson disease.

Authors:  M B Spina; G Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

4.  L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice.

Authors:  Maria E Reveron; Katerina V Savelieva; Jennifer L Tillerson; Alison L McCormack; Donato A Di Monte; Gary W Miller
Journal:  Neurotoxicology       Date:  2002-10       Impact factor: 4.294

Review 5.  Does levodopa accelerate Parkinson's disease?

Authors:  T Simuni; M B Stern
Journal:  Drugs Aging       Date:  1999-06       Impact factor: 3.923

6.  Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.

Authors:  J M Brown; G R Hanson; A E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2001-03       Impact factor: 4.030

7.  Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration.

Authors:  Jannine G Truong; Kristi S Rau; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2003-08-08       Impact factor: 4.432

8.  Nigral type I astrocytes release a soluble factor that increases dopaminergic neuron survival through mechanisms distinct from basic fibroblast growth factor.

Authors:  E K O'Malley; B A Sieber; R S Morrison; I B Black; C F Dreyfus
Journal:  Brain Res       Date:  1994-05-30       Impact factor: 3.252

Review 9.  Levodopa neurotoxicity: experimental studies versus clinical relevance.

Authors:  P G Jenner; M F Brin
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

Review 10.  Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules.

Authors:  J P Henry; D Botton; C Sagne; M F Isambert; C Desnos; V Blanchard; R Raisman-Vozari; E Krejci; J Massoulie; B Gasnier
Journal:  J Exp Biol       Date:  1994-11       Impact factor: 3.312

View more
  10 in total

Review 1.  VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.

Authors:  Lee E Eiden; Eberhard Weihe
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 2.  The vesicular monoamine transporter 2: an underexplored pharmacological target.

Authors:  Alison I Bernstein; Kristen A Stout; Gary W Miller
Journal:  Neurochem Int       Date:  2014-01-04       Impact factor: 3.921

Review 3.  Monoamine transporters: vulnerable and vital doorkeepers.

Authors:  Zhicheng Lin; Juan J Canales; Thröstur Björgvinsson; Morgane Thomsen; Hong Qu; Qing-Rong Liu; Gonzalo E Torres; S Barak Caine
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

4.  Three types of tyrosine hydroxylase-positive CNS neurons distinguished by dopa decarboxylase and VMAT2 co-expression.

Authors:  Eberhard Weihe; Candan Depboylu; Burkhard Schütz; Martin K-H Schäfer; Lee E Eiden
Journal:  Cell Mol Neurobiol       Date:  2006-05-31       Impact factor: 5.046

Review 5.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

6.  Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels.

Authors:  Michael K Sievert; Abdol R Hajipour; Arnold E Ruoho
Journal:  Anal Biochem       Date:  2007-05-03       Impact factor: 3.365

Review 7.  Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.

Authors:  Thomas S Guillot; Gary W Miller
Journal:  Mol Neurobiol       Date:  2009-03-04       Impact factor: 5.590

8.  VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.

Authors:  Tonya N Taylor; W Michael Caudle; Gary W Miller
Journal:  Parkinsons Dis       Date:  2011-02-21

9.  A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease.

Authors:  Vignayanandam Ravindernath-Jayashree Muddapu; Karthik Vijayakumar; Keerthiga Ramakrishnan; V Srinivasa Chakravarthy
Journal:  Front Neurosci       Date:  2022-04-19       Impact factor: 5.152

10.  Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson's disease motor symptoms without neuronal degeneration in adult mice.

Authors:  Elsa Isingrini; Chloé Guinaudie; Léa C Perret; Quentin Rainer; Luc Moquin; Alain Gratton; Bruno Giros
Journal:  Sci Rep       Date:  2017-09-29       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.